Healthcare - Biotechnology - NASDAQ - US
$ 16.14
-5.34 %
$ 103 M
Market Cap
-1.86
P/E
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC.[ Read More ]
The intrinsic value of one ASMB stock under the base case scenario is HIDDEN Compared to the current market price of 16.1 USD, Assembly Biosciences, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ASMB
FINANCIALS
7.16 M
REVENUE
-64.6 M
OPERATING INCOME
-61.2 M
NET INCOME
22.7 M
OPERATING CASH FLOW
-69.1 M
INVESTING CASH FLOW
13.8 M
FINANCING CASH FLOW
6.84 M
REVENUE
-11 M
OPERATING INCOME
-9.61 M
NET INCOME
-15.2 M
OPERATING CASH FLOW
24.5 M
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Assembly Biosciences, Inc.
| Current Assets | 134 M |
| Cash & Short-Term Investments | 130 M |
| Receivables | 43 K |
| Other Current Assets | 3.5 M |
| Non-Current Assets | 3.68 M |
| Long-Term Investments | 0 |
| PP&E | 2.72 M |
| Other Non-Current Assets | 958 K |
| Current Liabilities | 39.2 M |
| Accounts Payable | 461 K |
| Short-Term Debt | 1.22 M |
| Other Current Liabilities | 37.5 M |
| Non-Current Liabilities | 57.1 M |
| Long-Term Debt | 1.12 M |
| Other Non-Current Liabilities | 56 M |
EFFICIENCY
Earnings Waterfall
Assembly Biosciences, Inc.
| Revenue | 7.16 M |
| Cost Of Revenue | 48.9 M |
| Gross Profit | -41.7 M |
| Operating Expenses | 22.9 M |
| Operating Income | -64.6 M |
| Other Expenses | -3.42 M |
| Net Income | -61.2 M |
RATIOS
-582.67%
GROSS MARGIN
-902.50%
OPERATING MARGIN
-854.78%
NET MARGIN
-148.98%
ROE
-44.54%
ROA
-157.39%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Assembly Biosciences, Inc.
| Net Income | -61.2 M |
| Depreciation & Amortization | 450 K |
| Capital Expenditures | -255 K |
| Stock-Based Compensation | 5.12 M |
| Change in Working Capital | 76.3 M |
| Others | 86.7 M |
| Free Cash Flow | 22.5 M |
Wall Street Analysts Price Targets
Assembly Biosciences, Inc.
Wall Street analysts predict an average 1-year price target for ASMB of $35.5 , with forecasts ranging from a low of $35 to a high of $36 .
ASMB Lowest Price Target
Wall Street Target
35 USD
116.85%
ASMB Average Price Target
Wall Street Target
35.5 USD
119.95%
ASMB Highest Price Target
Wall Street Target
36 USD
123.05%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Assembly Biosciences, Inc.
Sold
0-3 MONTHS
5.24 K USD 2
3-6 MONTHS
67.9 K USD 4
6-9 MONTHS
65.4 K USD 4
9-12 MONTHS
329 USD 1
Bought
146 K USD 1
0-3 MONTHS
3.16 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
793 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Oct 08, 2024
|
Bought 146 K USD
|
Schornstein Alexander
10 percent owner |
+ 10000
|
14.58 USD |
|
1 month ago
Oct 03, 2024
|
Sell 2.33 K USD
|
White Nicole S
Chief Manufacturing Officer |
- 157
|
14.81 USD |
|
1 month ago
Oct 03, 2024
|
Sell 2.92 K USD
|
Okazaki Jason A
CEO and President |
- 197
|
14.81 USD |
|
3 months ago
Aug 02, 2024
|
Sell 11.2 K USD
|
White Nicole S
Chief Manufacturing Officer |
- 785
|
14.2325 USD |
|
3 months ago
Aug 02, 2024
|
Sell 14 K USD
|
Okazaki Jason A
CEO and President |
- 981
|
14.2325 USD |
|
4 months ago
Jul 05, 2024
|
Bought 55.6 K USD
|
Schornstein Alexander
10 percent owner |
+ 4438
|
12.52 USD |
|
4 months ago
Jul 03, 2024
|
Bought 56.1 K USD
|
Schornstein Alexander
10 percent owner |
+ 4562
|
12.29 USD |
|
5 months ago
Jun 17, 2024
|
Bought 180 USD
|
GILEAD SCIENCES, INC.
10 percent owner |
+ 179500
|
0.001 USD |
|
5 months ago
Jun 17, 2024
|
Bought 3.05 M USD
|
GILEAD SCIENCES, INC.
10 percent owner |
+ 179500
|
17 USD |
|
5 months ago
May 23, 2024
|
Sell 358 USD
|
Bjorkquist Jeanette M
Principal Accounting Officer |
- 24
|
14.9338 USD |
|
5 months ago
May 23, 2024
|
Sell 31.6 K USD
|
McHutchison John G
Director |
- 2117
|
14.9338 USD |
|
5 months ago
May 23, 2024
|
Sell 2.57 K USD
|
White Nicole S
Chief Manufacturing Officer |
- 172
|
14.9338 USD |
|
5 months ago
May 23, 2024
|
Sell 8.2 K USD
|
Okazaki Jason A
CEO and President |
- 549
|
14.9338 USD |
|
6 months ago
Apr 30, 2024
|
Sell 15.9 K USD
|
White Nicole S
Chief Manufacturing Officer |
- 1255
|
12.7068 USD |
|
6 months ago
Apr 30, 2024
|
Sell 19.9 K USD
|
Okazaki Jason A
CEO and President |
- 1569
|
12.7068 USD |
|
7 months ago
Apr 01, 2024
|
Sell 15.8 K USD
|
McHutchison John G
Director |
- 1206
|
13.0719 USD |
|
7 months ago
Apr 01, 2024
|
Sell 1.49 K USD
|
Bjorkquist Jeanette M
Principal Accounting Officer |
- 114
|
13.0719 USD |
|
7 months ago
Apr 01, 2024
|
Sell 2.58 K USD
|
White Nicole S
Chief Manufacturing Officer |
- 197
|
13.0719 USD |
|
7 months ago
Apr 01, 2024
|
Sell 4.63 K USD
|
Okazaki Jason A
CEO and President |
- 354
|
13.0719 USD |
|
7 months ago
Mar 27, 2024
|
Sell 5.05 K USD
|
Okazaki Jason A
CEO and President |
- 392
|
12.87 USD |
|
9 months ago
Jan 18, 2024
|
Bought 276 K USD
|
Schornstein Alexander
10 percent owner |
+ 345086
|
0.8 USD |
|
10 months ago
Jan 17, 2024
|
Bought 235 K USD
|
Schornstein Alexander
10 percent owner |
+ 299994
|
0.784 USD |
|
11 months ago
Nov 21, 2023
|
Bought 66.7 K USD
|
Schornstein Alexander
10 percent owner |
+ 100000
|
0.667 USD |
|
11 months ago
Nov 20, 2023
|
Bought 215 K USD
|
Schornstein Alexander
10 percent owner |
+ 300000
|
0.718 USD |
|
1 year ago
Nov 17, 2023
|
Sell 329 USD
|
White Nicole S
Chief Manufacturing Officer |
- 477
|
0.689 USD |
|
1 year ago
Oct 03, 2023
|
Sell 1.5 K USD
|
White Nicole S
Chief Manufacturing Officer |
- 1891
|
0.7953 USD |
|
1 year ago
Oct 03, 2023
|
Sell 1.5 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 1891
|
0.7953 USD |
|
1 year ago
Oct 03, 2023
|
Sell 1.88 K USD
|
Okazaki Jason A
CEO and President |
- 2363
|
0.7953 USD |
|
1 year ago
Aug 02, 2023
|
Sell 10.3 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 9461
|
1.0879 USD |
|
1 year ago
Aug 02, 2023
|
Sell 12.9 K USD
|
Okazaki Jason A
CEO and President |
- 11827
|
1.0879 USD |
|
1 year ago
Jul 24, 2023
|
Sell 900 USD
|
Bjorkquist Jeanette M
Principal Accounting Officer |
- 844
|
1.0668 USD |
|
1 year ago
May 30, 2023
|
Sell 4.05 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 4232
|
0.9561 USD |
|
1 year ago
May 23, 2023
|
Sell 27 K USD
|
McHutchison John G
Director |
- 25972
|
1.0403 USD |
|
1 year ago
May 23, 2023
|
Sell 285 USD
|
Bjorkquist Jeanette M
Principal Accounting Officer |
- 274
|
1.0403 USD |
|
1 year ago
May 23, 2023
|
Sell 6.83 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 6561
|
1.0403 USD |
|
1 year ago
May 23, 2023
|
Sell 6.83 K USD
|
Okazaki Jason A
CEO and President |
- 6561
|
1.0403 USD |
|
1 year ago
Mar 30, 2023
|
Sell 12.3 K USD
|
McHutchison John G
Director |
- 14883
|
0.8232 USD |
|
1 year ago
Mar 30, 2023
|
Sell 637 USD
|
Bjorkquist Jeanette M
Principal Accounting Officer |
- 774
|
0.8232 USD |
|
1 year ago
Mar 30, 2023
|
Sell 2.82 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 3421
|
0.8232 USD |
|
1 year ago
Mar 30, 2023
|
Sell 3.5 K USD
|
Okazaki Jason A
CEO and President |
- 4247
|
0.8232 USD |
|
1 year ago
Mar 27, 2023
|
Sell 4.78 K USD
|
Okazaki Jason A
CEO and President |
- 4693
|
1.0196 USD |
|
2 years ago
Aug 08, 2022
|
Sell 26.2 K USD
|
McHutchison John G
Chief Executive Officer |
- 12314
|
2.1277 USD |
|
2 years ago
Jul 25, 2022
|
Sell 4.48 K USD
|
Samar Michael P.
Chief Financial Officer |
- 2020
|
2.2174 USD |
|
2 years ago
May 31, 2022
|
Sell 8 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 4164
|
1.9224 USD |
|
2 years ago
Mar 29, 2022
|
Sell 4.95 K USD
|
Samar Michael P.
Chief Financial Officer |
- 2285
|
2.1674 USD |
|
2 years ago
Mar 29, 2022
|
Sell 2.25 K USD
|
Stamm Luisa M
Chief Medical Officer |
- 1038
|
2.1674 USD |
|
2 years ago
Mar 29, 2022
|
Sell 2.25 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 1038
|
2.1674 USD |
|
2 years ago
Mar 29, 2022
|
Sell 2.75 K USD
|
Okazaki Jason A
Chief Operating Officer |
- 1269
|
2.1674 USD |
|
2 years ago
Mar 29, 2022
|
Sell 10 K USD
|
McHutchison John G
CEO and President |
- 4614
|
2.1674 USD |
|
2 years ago
Mar 28, 2022
|
Sell 10.4 K USD
|
Okazaki Jason A
Chief Operating Officer |
- 4617
|
2.2445 USD |
|
3 years ago
Aug 09, 2021
|
Sell 43.8 K USD
|
McHutchison John G
CEO and President |
- 12156
|
3.6016 USD |
|
3 years ago
May 27, 2021
|
Sell 16.6 K USD
|
Delaney William E IV
Chief Scientific Officer |
- 4129
|
4.0294 USD |
|
3 years ago
Dec 14, 2020
|
Sell 7.98 K USD
|
Papkoff Jacqueline Sybil
SVP-CSO Microbiome |
- 1297
|
6.1548 USD |
|
4 years ago
Nov 09, 2020
|
Sell 22.4 K USD
|
Stamm Luisa M
Chief Medical Officer |
- 4397
|
5.0952 USD |
|
4 years ago
Aug 07, 2020
|
Sell 248 K USD
|
McHutchison John G
CEO and President |
- 11395
|
21.7558 USD |
|
4 years ago
Aug 07, 2020
|
Sell 17 K USD
|
McHutchison John G
CEO and President |
- 756
|
22.4995 USD |
|
4 years ago
Mar 30, 2020
|
Sell 17.8 K USD
|
Papkoff Jacqueline Sybil
SVP-CSO Microbiome |
- 1254
|
14.2192 USD |
|
4 years ago
Mar 31, 2020
|
Sell 118 K USD
|
Colonno Richard James
EVP & CSO, Virology Ops |
- 7812
|
15.044 USD |
|
4 years ago
Dec 13, 2019
|
Sell 30.7 K USD
|
Papkoff Jacqueline Sybil
SVP-CSO Microbiome |
- 1460
|
21.0011 USD |
|
4 years ago
Dec 12, 2019
|
Sell 827 K USD
|
Colonno Richard James
EVP & CSO, Virology Ops |
- 33061
|
25.0016 USD |
|
6 years ago
Sep 05, 2018
|
Sell 610 K USD
|
Lopatin Uri A
Chief Med. Off., VP Res. Dev. |
- 15204
|
40.0912 USD |
|
6 years ago
Sep 06, 2018
|
Sell 13.4 K USD
|
Lopatin Uri A
Chief Med. Off., VP Res. Dev. |
- 336
|
40.006 USD |
|
6 years ago
Jul 19, 2018
|
Bought 50.1 K USD
|
Small Derek A
CEO and President |
+ 1200
|
41.7692 USD |
|
6 years ago
Jul 19, 2018
|
Bought 49.4 K USD
|
Small Derek A
CEO and President |
+ 1200
|
41.1902 USD |
|
6 years ago
Jul 02, 2018
|
Sell 38.5 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
38.503 USD |
|
6 years ago
Jun 01, 2018
|
Sell 42.5 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
42.47 USD |
|
6 years ago
May 01, 2018
|
Sell 43.1 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
43.06 USD |
|
6 years ago
Apr 17, 2018
|
Bought 14.8 K USD
|
EcoR1 Capital Fund Qualified, L.P.
10 percent owner |
+ 246
|
60 USD |
|
6 years ago
Apr 13, 2018
|
Bought 58 K USD
|
EcoR1 Capital Fund Qualified, L.P.
10 percent owner |
+ 967
|
60 USD |
|
6 years ago
Apr 02, 2018
|
Sell 49.3 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
49.32 USD |
|
6 years ago
Mar 01, 2018
|
Sell 56.4 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
56.37 USD |
|
6 years ago
Feb 01, 2018
|
Sell 46.9 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
46.86 USD |
|
6 years ago
Jan 02, 2018
|
Sell 45 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
45.04 USD |
|
6 years ago
Dec 01, 2017
|
Sell 49.4 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
49.37 USD |
|
7 years ago
Nov 01, 2017
|
Sell 29.6 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
29.55 USD |
|
7 years ago
Oct 16, 2017
|
Sell 33.7 K USD
|
RINGO WILLIAM R
Director |
- 1000
|
33.7 USD |
|
7 years ago
May 12, 2017
|
Sell 76.1 K USD
|
RINGO WILLIAM R
Director |
- 3461
|
22 USD |
|
8 years ago
Feb 11, 2016
|
Bought 8.65 K USD
|
Small Derek A
CEO and President |
+ 1555
|
5.561 USD |
|
8 years ago
Feb 10, 2016
|
Bought 46.6 K USD
|
Small Derek A
CEO and President |
+ 8445
|
5.522 USD |
|
10 years ago
May 27, 2014
|
Bought 12 K USD
|
ELLISON RUSSELL H
Chief Executive Officer |
+ 13000
|
0.92 USD |
|
10 years ago
May 23, 2014
|
Bought 13.6 K USD
|
ELLISON RUSSELL H
Chief Executive Officer |
+ 15000
|
0.9069 USD |
|
10 years ago
May 22, 2014
|
Bought 4.5 K USD
|
ELLISON RUSSELL H
Chief Executive Officer |
+ 5000
|
0.9 USD |
|
10 years ago
May 23, 2014
|
Bought 880 USD
|
BARRETT DAVID JONATHAN
Chief Financial Officer |
+ 1000
|
0.88 USD |
|
10 years ago
May 22, 2014
|
Bought 5.14 K USD
|
BARRETT DAVID JONATHAN
Chief Financial Officer |
+ 5980
|
0.86 USD |
|
10 years ago
May 21, 2014
|
Bought 8.7 K USD
|
ELLISON RUSSELL H
Chief Executive Officer |
+ 10000
|
0.8698 USD |
|
10 years ago
May 20, 2014
|
Bought 35.2 K USD
|
BARRETT DAVID JONATHAN
Chief Financial Officer |
+ 40000
|
0.88 USD |
|
11 years ago
Feb 05, 2013
|
Bought 14.6 K USD
|
ELLISON RUSSELL H
Chief Executive Officer |
+ 5624
|
2.59 USD |
|
11 years ago
Feb 04, 2013
|
Bought 23.6 K USD
|
ELLISON RUSSELL H
Chief Executive Officer |
+ 9376
|
2.52 USD |
7. News
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
zacks.com
- 2 months ago
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
globenewswire.com
- 4 months ago
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
globenewswire.com
- 5 months ago
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D --
globenewswire.com
- 5 months ago
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2024.
globenewswire.com
- 6 months ago
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.
globenewswire.com
- 7 months ago
Assembly Biosciences Announces Effective Date of Reverse Stock Split
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –
globenewswire.com
- 9 months ago
Assembly Biosciences Provides Anticipated Development Milestones for 2024
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
globenewswire.com
- 10 months ago
5 Penny Stocks With Big Black Friday Stock Market News
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news, rumors, and breakthroughs – allowing traders to potentially lock in short-term gains.
pennystocks.com
- 11 months ago
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023.
globenewswire.com
- 1 year ago
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.
globenewswire.com
- 1 year ago
Why Are Stocks Down Today?
Stocks are down today and investors wondering why are in the right place as we have all the details they need to know about on Tuesday! The big reason that stocks are down today has to do with the latest retail sales report.
investorplace.com
- 1 year ago
8. Profile Summary
Assembly Biosciences, Inc. ASMB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 103 M
Dividend Yield
0.00%
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Contact
331 Oyster Point Boulevard, South San Francisco, CA, 94080
https://www.assemblybio.com
IPO Date
Dec. 17, 2010
Employees
65
Officers
Dr. Uri A. Lopatin M.D.
Co-Founder and Clinical & Scientific Advisor
Dr. Anuj Gaggar M.D., Ph.D.
Chief Medical Officer
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Jeanette M Bjorkquist
Executive Director of Accounting & Treasury
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR
Chief Human Resources Officer
Dr. Adam Zlotnick
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Amy Figueroa C.F.A.
Investor Relations Consultant
Mr. Thomas E. Rollins
Executive Officer
Mr. Jason A. Okazaki
Chief Executive Officer, President & Director
Dr. William E. Delaney IV, Ph.D.
Chief Scientific Officer